{"product_id":"exelixis-bcg-matrix","title":"Exelixis Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious about Exelixis's product portfolio and market position? This preview offers a glimpse into their potential Stars, Cash Cows, Dogs, and Question Marks. To truly unlock strategic advantage and make informed decisions about resource allocation and future investments, you need the complete BCG Matrix analysis.\u003c\/p\u003e\n\u003cp\u003eDon't let uncertainty guide your strategy. Purchase the full Exelixis BCG Matrix for a comprehensive breakdown of each product's quadrant placement, backed by data-driven insights and actionable recommendations. Equip yourself with the clarity needed to navigate market dynamics and drive growth.\u003c\/p\u003e\n\u003cp\u003eThis is your opportunity to gain a competitive edge. The full Exelixis BCG Matrix isn't just a report; it's a strategic roadmap. Secure your copy today and transform your understanding of Exelixis's market performance into powerful, actionable business intelligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCabometyx in Neuroendocrine Tumors (NET)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCabometyx's recent approvals for neuroendocrine tumors (NET) in March 2025 (U.S. FDA) and July 2025 (European Commission) mark a significant expansion. This new indication is quickly capturing market share, achieving approximately 35% of new patient starts in the second-line plus oral therapy segment for NET during Q2 2025.\u003c\/p\u003e\n\u003cp\u003eThis strong uptake is a positive driver for Exelixis' revenue growth. The company anticipates this positive trend to persist, potentially leading to upward revisions in its 2025 financial guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCabometyx in Renal Cell Carcinoma (RCC)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCabometyx stands out as a dominant force in the renal cell carcinoma (RCC) market, holding its position as the leading prescribed tyrosine kinase inhibitor (TKI). Furthermore, it is the top choice for TKI plus immunotherapy combinations in the crucial first-line treatment setting for RCC. This strong market penetration directly fuels Exelixis' revenue streams.\u003c\/p\u003e\n\u003cp\u003eThe market share of Cabometyx in RCC has demonstrated a steady upward trajectory, climbing to 45% by the second quarter of 2025. This represents a notable increase from the 41% market share recorded in the same period of the previous year. Such consistent growth underscores its therapeutic value and commercial success.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCabometyx in Hepatocellular Carcinoma (HCC)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCabometyx's use in hepatocellular carcinoma (HCC) for patients who have already received sorafenib treatment is a key factor in its market position. This established indication provides a consistent revenue source for Exelixis within the competitive oncology sector.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Cabometyx continued to be a significant contributor to Exelixis's portfolio. While specific HCC revenue figures are often bundled, the drug's overall performance in treating advanced renal cell carcinoma and HCC, among other indications, supported a strong market presence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCabometyx in Differentiated Thyroid Cancer (DTC)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCabometyx is a key player in Exelixis's portfolio, holding a significant position within the differentiated thyroid cancer (DTC) market. Its approval for adult and pediatric patients with advanced or metastatic DTC, particularly those who have progressed on prior therapies and are refractory to radioactive iodine, highlights its therapeutic value and expands Exelixis's market reach beyond its established indications.\u003c\/p\u003e\n\u003cp\u003eWhile the DTC market segment might be smaller compared to renal cell carcinoma (RCC) or neuroendocrine tumors (NET), it represents a crucial area for Cabometyx's continued growth and utility. This expansion into DTC demonstrates the drug's versatility and its ability to address unmet needs in various oncology settings.\u003c\/p\u003e\n\u003cp\u003eThe financial implications of this indication are noteworthy. For instance, in 2023, Exelixis reported total net product revenue of $1.4 billion, with Cabometyx being the primary driver. While specific revenue breakdowns for DTC are not publicly detailed, its inclusion in the treatment paradigm for this indication contributes to the overall revenue stream and market share of Cabometyx.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eCabometyx Approved for DTC:\u003c\/strong\u003e Indicated for advanced or metastatic differentiated thyroid cancer in adult and pediatric patients who have progressed on prior VEGFR-targeted therapy and are radioactive iodine-refractory or ineligible.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Expansion:\u003c\/strong\u003e This DTC indication broadens Cabometyx's market reach, complementing its established use in other cancer types.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRevenue Contribution:\u003c\/strong\u003e Cabometyx is a significant revenue generator for Exelixis, contributing to the company's overall financial performance. In 2023, Exelixis's net product revenue reached $1.4 billion, with Cabometyx as the lead product.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTherapeutic Value:\u003c\/strong\u003e The drug addresses an unmet need in DTC, offering a treatment option for patients with limited alternatives.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Expansion of Cabozantinib Franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExelixis is aggressively expanding its cabozantinib franchise by pursuing new indications and deepening market penetration. The company anticipates sustained growth in cabozantinib revenue, projecting a strong full-year 2025 performance. This strategic emphasis is designed to fully leverage the significant potential of its flagship product.\u003c\/p\u003e\n\u003cp\u003eCabozantinib's strategic expansion is a key driver for Exelixis, reflecting a commitment to maximizing its market presence. The company's financial outlook for 2025 highlights continued revenue growth for cabozantinib, underscoring its importance to the franchise. This focus on broadening the drug's applications and reach is central to Exelixis's growth strategy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eCabozantinib Franchise Growth:\u003c\/strong\u003e Exelixis is actively pursuing new indications and market penetration for its cabozantinib franchise.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2025 Financial Guidance:\u003c\/strong\u003e The company has reaffirmed strong full-year 2025 financial guidance, expecting continued growth in cabozantinib revenue.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Focus:\u003c\/strong\u003e The strategy aims to maximize the potential of cabozantinib, its leading product, through expanded use and market access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCabometyx: Exelixis's Revenue Driver with Diverse Cancer Indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCabometyx's expansion into neuroendocrine tumors (NET) and differentiated thyroid cancer (DTC) positions it as a star product for Exelixis. Its strong market share in renal cell carcinoma (RCC) and growing presence in hepatocellular carcinoma (HCC) further solidify this status. These diverse indications, coupled with aggressive pursuit of new opportunities, drive significant revenue growth for Exelixis.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eKey Indications\u003c\/th\u003e\n\u003cth\u003e2023 Revenue (Approx.)\u003c\/th\u003e\n\u003cth\u003eMarket Share (Q2 2025 Est.)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCabometyx\u003c\/td\u003e\n\u003ctd\u003eRCC, HCC, DTC, NET\u003c\/td\u003e\n\u003ctd\u003e$1.4 Billion (Total Exelixis Net Product Revenue)\u003c\/td\u003e\n\u003ctd\u003eRCC: 45% (1st Line TKI+IO)\u003cbr\u003eNET: 35% (2nd Line+ Oral)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThe Exelixis BCG Matrix analyzes its product portfolio based on market growth and share, guiding investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExelixis BCG Matrix: A visual tool that simplifies complex portfolio analysis, reducing the pain of strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCabozantinib Franchise Overall\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe cabozantinib franchise, comprising Cabometyx and Cometriq, stands as Exelixis's leading revenue generator.  In the second quarter of 2025, U.S. net product revenues for this franchise surged by 19% year-over-year, reaching $520 million. \u003c\/p\u003e\n\u003cp\u003eThis robust financial performance underscores the franchise's substantial cash-generating capacity. The consistent strength of cabozantinib allows Exelixis to allocate resources towards critical areas such as advancing its pipeline and executing share repurchase programs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Profit Margins from Established Indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCabometyx enjoys substantial profit margins in its established indications like renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and differentiated thyroid cancer (DTC). This profitability stems from a strong competitive edge and reduced marketing expenses in these mature markets, allowing Exelixis to generate consistent cash flow. For instance, in 2023, Cabometyx sales reached approximately $1.2 billion, underscoring its dominance and profitability in these key therapeutic areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStable Revenue from Long-Term Prescriptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCabometyx's established indications, particularly in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), contribute significantly to Exelixis's \"cash cow\" status. The mature nature of these treatment areas translates into a consistent and predictable stream of prescriptions and refills. This stability is crucial for Exelixis, allowing for reliable revenue generation that underpins its financial health and strategic planning.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Cabometyx continued to demonstrate strong performance, with net product revenue reaching approximately $1.2 billion for the first nine months of the year. This consistent revenue from long-term prescriptions provides a solid foundation for Exelixis to invest in its pipeline and explore new market opportunities, reinforcing its position as a reliable performer in the oncology sector.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalties from International Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eExelixis benefits significantly from royalties generated through international partnerships, particularly for its drug cabozantinib. These collaborations allow the company to earn revenue without bearing the direct costs of sales and marketing in those specific regions.\u003c\/p\u003e\n\u003cp\u003eKey partners like Ipsen and Takeda contribute to these royalty streams. For instance, in 2023, Exelixis reported collaboration and royalty revenue of $390 million, a substantial portion of which stems from these international agreements.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eRoyalties from cabozantinib sales outside the U.S.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePartnerships with companies like Ipsen and Takeda drive revenue.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThese royalties represent a significant cash flow without direct operational expenses for Exelixis in those markets.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eIn 2023, collaboration and royalty revenue reached $390 million.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDisciplined Capital Allocation and Share Repurchases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eExelixis leverages the substantial cash generated by its Cabozantinib products to implement a strategic capital allocation plan. This includes a robust program of share repurchases, aimed at enhancing shareholder value and improving the company's capital efficiency.\u003c\/p\u003e\n\u003cp\u003eThe company's commitment to returning capital to shareholders is evident in its buyback activities. As of the second quarter of 2025, Exelixis had successfully repurchased $796.3 million of its common stock. This substantial repurchase program underscores the company's confidence in its financial health and its strategy to optimize its capital structure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eDisciplined Capital Allocation:\u003c\/strong\u003e Exelixis prioritizes returning value to shareholders through strategic capital deployment.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eShare Repurchase Program:\u003c\/strong\u003e The company actively engages in share buybacks, funded by strong cash flows.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$796.3 Million Repurchased:\u003c\/strong\u003e As of June 30, 2025, Exelixis had bought back this significant amount of its common stock.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eShareholder Value Focus:\u003c\/strong\u003e These actions demonstrate a commitment to enhancing shareholder returns and optimizing the capital structure.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCabozantinib: Exelixis's Billion-Dollar Revenue Driver\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe cabozantinib franchise, particularly Cabometyx, functions as Exelixis's primary cash cow. Its strong performance in established indications like renal cell carcinoma and hepatocellular carcinoma generates consistent, predictable revenue streams. This stability allows Exelixis to fund pipeline development and shareholder returns.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Cabometyx's net product revenue for the first nine months approximated $1.2 billion, highlighting its robust market presence and profitability. This consistent cash generation from long-term prescriptions solidifies its role as a reliable financial engine for the company.\u003c\/p\u003e\n\u003cp\u003eRoyalties from international cabozantinib sales, driven by partnerships with firms like Ipsen and Takeda, further bolster Exelixis's cash flow. In 2023, these collaboration and royalty revenues amounted to $390 million, representing significant income without direct market operational costs.\u003c\/p\u003e\n\u003cp\u003eThe substantial cash generated by cabozantinib enables Exelixis to actively repurchase its stock, demonstrating a commitment to shareholder value. By the second quarter of 2025, the company had repurchased $796.3 million of its common stock, underscoring its financial strength and capital efficiency.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct Franchise\u003c\/th\u003e\n\u003cth\u003eKey Indications\u003c\/th\u003e\n\u003cth\u003e2024 (9 Months) Revenue (Approx.)\u003c\/th\u003e\n\u003cth\u003e2023 Royalty Revenue\u003c\/th\u003e\n\u003cth\u003e2025 (Q2) Share Repurchases\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCabozantinib (Cabometyx \u0026amp; Cometriq)\u003c\/td\u003e\n\u003ctd\u003eRCC, HCC, DTC\u003c\/td\u003e\n\u003ctd\u003e$1.2 Billion\u003c\/td\u003e\n\u003ctd\u003e$390 Million (Total Collaboration \u0026amp; Royalty)\u003c\/td\u003e\n\u003ctd\u003e$796.3 Million (Total Common Stock Repurchased)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eExelixis BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe BCG Matrix document you are currently previewing is the identical, fully formatted report you will receive immediately after completing your purchase. This ensures you get exactly what you see, with no watermarks or demo content, ready for immediate strategic application. You can confidently use this preview as a direct representation of the professional-grade BCG Matrix analysis that will be yours to download and utilize. This means no surprises, just a complete and actionable tool for your business planning needs. Once purchased, this comprehensive BCG Matrix report is instantly available for your editing, presentation, or integration into your broader strategic initiatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610906280313,"sku":"exelixis-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/exelixis-bcg-matrix.png?v=1754748452","url":"https:\/\/growthsharematrix.com\/products\/exelixis-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}